Information Provided By: 
Fly News Breaks for December 30, 2019
BGNE
Dec 30, 2019 | 09:27 EDT
Guggenheim analyst Michael Schmidt said Chinese regulatory approval of tislelizumab for the treatment of patients with Hodgkin's lymphoma is in line with his expectation and may remove a "small overhang" on BeiGene shares. It is also important that approval came before the end of 2019, which qualifies tislelizumab for price negotiation and possible inclusion in the National Reimbursement Drug List in late 2020, Schmidt said. He keeps a Neutral rating on BeiGene shares.
News For BGNE From the Last 2 Days
BGNE
Apr 24, 2024 | 07:26 EDT
TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.
